Instead, these therapeutics have been used in ER+/HER2− postmenopausal breast cancer patients who are refractory to endocrine therapies—acquired genetic alterations activating the PI3K–AKT–mTOR pathway frequently drive resistance to endocrine therapies (Nunnery and Mayer, 2020). Here, MTOR is linked to breast carcinoma.